Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.45 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.45 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.45 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
| ▸ | NOXO1 | Q8NFA2 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19751623 | 1.00 | F2 (0.45) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL4974927 | 0.97 | F2 (0.44) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL19751667 | 0.97 | F2 (0.44) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL19751762 | 0.92 | F2 (0.47) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL10109654 | 0.91 | CNR1 (0.44) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL2731793 | 0.91 | PRSS1 (0.46) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL19751638 | 0.91 | PRSS1 (0.46) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL4966737 | 0.91 | F2 (0.48) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL4970859 | 0.88 | PRSS1 (0.49) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL19751622 | 0.88 | F2 (0.45) | F2PRSS1PRSS2PRSS3TPSAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731982-B2 | Biotin derivatives | Life Technologies Corporation | 2023-08-22 | — | — | US | disclosed |
| US-20190322681-A1 | Biotin Derivatives | LIFE TECHNOLOGIES AS (NO) | 2019-10-24 | — | — | US | disclosed |
| EP-2633062-B1 | BIOTIN DERIVATIVES | LIFE TECHNOLOGIES CORP (US) | 2017-12-27 | — | — | EP | disclosed |
| US-20170174700-A1 | Biotin Derivatives | Life Technologies Corporation | 2017-06-22 | — | — | US | disclosed |
| US-9567346-B2 | Biotin derivatives | Life Technologies Corporation (US) | 2017-02-14 | — | — | US | disclosed |
| US-20140011255-A1 | Biotin Derivatives | Life Technologies Corporation (US) | 2014-01-09 | — | — | US | disclosed |
| WO-2012058635-A1 | BIOTIN DERIVATIVES | Life Technologies Corporation (US) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731982-B2 | Biotin derivatives | BTD, HLCS, BRI3BP | F2 3416/4885PRSS1 1659/4885PRSS2 1369/4885 |
| US-20140011255-A1 | Biotin Derivatives | BTD, HLCS, BRI3BP | F2 3416/4885PRSS1 1659/4885PRSS2 1369/4885 |
| US-20190322681-A1 | Biotin Derivatives | BTD, HLCS, BRI3BP | F2 3416/4885PRSS1 1659/4885PRSS2 1369/4885 |
| US-20170174700-A1 | Biotin Derivatives | BTD, HLCS, BRI3BP | F2 3416/4885PRSS1 1659/4885PRSS2 1369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.